5月14日，据CDE官网消息，石药集团中奇制药技术（石家庄）有限公司联合申请药品“重组抗PD-1全人源单克隆抗体注射液”，获得临床试验默示许可，受理号CXSL2400173。
公示信息显示，药品“重组抗PD-1全人源单克隆抗体注射液”适应症：本品联合SYS6002用于晚期尿路上皮癌及其他晚期实体瘤。
石药集团中奇制药技术（石家庄）有限公司药品申请临床试验默示许可获受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.